1.99  0 (0%)		10-24 16:00
Open: 2.03 High: 2.085 Volume: 495,530		Pre. Close: 1.99 Low: 1.97 Market Cap: 135(M)

Short term
Mid term
Targets	6-month :	2.47	1-year :	2.88
Resists	First :	2.11	Second :	2.47
Pivot price	1.95
Supports	First :	1.53	Second :	1.28
MAs	MA(5) :	2.12	MA(20) :	1.96
	MA(100) :	1.76	MA(250) :	1.87
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	50.8	D(3) :	62.6
RSI	RSI(14): 48.5
52-week	High :	4.67	Low :	1.04

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ CLYM ] has closed below upper band by 44.2%. Bollinger Bands are 41.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	2.09 - 2.1	2.1 - 2.11
Low:	1.94 - 1.96	1.96 - 1.97
Close:	1.97 - 1.99	1.99 - 2.01

Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Tue, 21 Oct 2025
Climb Bio (NASDAQ: CLYM) grants options for 360,000 shares at $2.32 to new hires - Stock Titan

Tue, 21 Oct 2025
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy - GlobeNewswire

Fri, 17 Oct 2025
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - Stock Titan

Fri, 17 Oct 2025
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 - Yahoo Finance

Thu, 16 Oct 2025
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity - Climb Bio (NASDAQ:CLYM) - Benzinga

Thu, 16 Oct 2025
William Blair Initiates Coverage of Climb Bio (CLYM) with Outperform Recommendation - Nasdaq

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	68 (M)
Shares Float	27 (M)
Held by Insiders	6.4 (%)
Held by Institutions	81.7 (%)
Shares Short	919 (K)
Shares Short P.Month	1,210 (K)

EPS	-0.02
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.74
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-15.9 %
Return on Equity (ttm)	-23 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-40 (M)
Levered Free Cash Flow	-23 (M)

PE Ratio	-99.5
PEG Ratio	0
Price to Book value	0.72
Price to Sales	0
Price to Cash Flow	-3.4

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.